Free Trial Information
BioCentury | Jun 6, 2016
Financial News

Protea Biosciences proposes follow-on

Protea Biosciences Group Inc. (OTCQB:PRGB), Morgantown, W.Va. Business: Diagnostic, Supply/Service Date announced: 2016-05-27 Type: Follow-on To be raised: Up to $19.6 million Shares: 3.1 million Price Prior: $0.20 Underwriter: Laidlaw Overallotment: 465,000 Note: The company...
Read More
BioCentury | May 11, 2015
Company News

vivoPharm, Protea Biosciences deal

...A$5.6 million ($4.6 million) in the same period. vivoPharm Pty Ltd. , Kent Town, Australia Protea Biosciences Group Inc....
Read More
BioCentury | May 4, 2015
Financial News

Protea Biosciences completes private placement of convertible preferred stock and warrants

Protea Biosciences Group Inc. (OTCQB:PRGB), Morgantown, W.Va. Business: Diagnostic, Supply/Service Date completed: 2015-04-27 Type: Private placement of convertible preferred stock and warrants Raised: $7.4 million Shares outstanding prior: 66.6 million Placement agent: Laidlaw Investors: Existing...
Read More
BioCentury | Jun 9, 2014
Company News

Protea Biosciences Group Inc., University of Southampton deal

...cells and fluids. Protea declined to disclose details, and the university could not be reached. Protea Biosciences Group Inc....
Read More
BioCentury | Feb 3, 2014
Company News

Protea Biosciences Inc., SRI International, General Electric, The George Washington University, U.S. Department of Defense infectious, other news

...data. Protea is responsible for developing nanophoton array chips for direct analysis of hepatocyte cells. Protea Biosciences...
Read More
BioCentury | Oct 10, 2013
Translation in Brief

Translational tidbits

...Cancer Undisclosed Collaboration to identify key targets in hematological cancers and generate antibodies against them Protea Biosciences...
Read More
BioCentury | Sep 30, 2013
Company News

Protea Biosciences Inc., Virginia Commonwealth University (VCU) deal

...The George Washington University (Washington, D.C.) under a 2010 deal (see BioCentury, Sept. 27, 2010). Protea Biosciences...
Read More
BioCentury | Sep 27, 2010
Company News

Protea Biosciences Inc., The George Washington University deal

...and biomolecules. Protea expects to launch the product next year. Financial terms were not disclosed. Protea Biosciences...
Read More
BioCentury | Jul 5, 2010
Clinical News

Recombinant lipase: Phase I/IIa started

...patients. Protea licensed exclusive U.S. marketing rights to the product from Mayoly-Spindler in May 2009. Protea Biosciences...
Read More
BioCentury | Aug 3, 2009
Company News

Protea Biosciences, Johns Hopkins University deal

...the use of albumin as a biomarker for myocardial infarction. Financial terms were not disclosed. Protea Biosciences...
Read More
Items per page:
1 - 10 of 14
BioCentury | Jun 6, 2016
Financial News

Protea Biosciences proposes follow-on

Protea Biosciences Group Inc. (OTCQB:PRGB), Morgantown, W.Va. Business: Diagnostic, Supply/Service Date announced: 2016-05-27 Type: Follow-on To be raised: Up to $19.6 million Shares: 3.1 million Price Prior: $0.20 Underwriter: Laidlaw Overallotment: 465,000 Note: The company...
Read More
BioCentury | May 11, 2015
Company News

vivoPharm, Protea Biosciences deal

...A$5.6 million ($4.6 million) in the same period. vivoPharm Pty Ltd. , Kent Town, Australia Protea Biosciences Group Inc....
Read More
BioCentury | May 4, 2015
Financial News

Protea Biosciences completes private placement of convertible preferred stock and warrants

Protea Biosciences Group Inc. (OTCQB:PRGB), Morgantown, W.Va. Business: Diagnostic, Supply/Service Date completed: 2015-04-27 Type: Private placement of convertible preferred stock and warrants Raised: $7.4 million Shares outstanding prior: 66.6 million Placement agent: Laidlaw Investors: Existing...
Read More
BioCentury | Jun 9, 2014
Company News

Protea Biosciences Group Inc., University of Southampton deal

...cells and fluids. Protea declined to disclose details, and the university could not be reached. Protea Biosciences Group Inc....
Read More
BioCentury | Feb 3, 2014
Company News

Protea Biosciences Inc., SRI International, General Electric, The George Washington University, U.S. Department of Defense infectious, other news

...data. Protea is responsible for developing nanophoton array chips for direct analysis of hepatocyte cells. Protea Biosciences...
Read More
BioCentury | Oct 10, 2013
Translation in Brief

Translational tidbits

...Cancer Undisclosed Collaboration to identify key targets in hematological cancers and generate antibodies against them Protea Biosciences...
Read More
BioCentury | Sep 30, 2013
Company News

Protea Biosciences Inc., Virginia Commonwealth University (VCU) deal

...The George Washington University (Washington, D.C.) under a 2010 deal (see BioCentury, Sept. 27, 2010). Protea Biosciences...
Read More
BioCentury | Sep 27, 2010
Company News

Protea Biosciences Inc., The George Washington University deal

...and biomolecules. Protea expects to launch the product next year. Financial terms were not disclosed. Protea Biosciences...
Read More
BioCentury | Jul 5, 2010
Clinical News

Recombinant lipase: Phase I/IIa started

...patients. Protea licensed exclusive U.S. marketing rights to the product from Mayoly-Spindler in May 2009. Protea Biosciences...
Read More
BioCentury | Aug 3, 2009
Company News

Protea Biosciences, Johns Hopkins University deal

...the use of albumin as a biomarker for myocardial infarction. Financial terms were not disclosed. Protea Biosciences...
Read More
Items per page:
1 - 10 of 14